Menu
Back to User profile » Dr Edward Kerwin
Papers published by Dr Edward Kerwin:
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
Shukla S, Shah D, Martin A, Risebrough NA, Kendall R, Vogelmeier CF, Boucot I, Tombs L, Bjermer L, Jones PW, Kerwin E, Compton C, Maltais F, Lipson DA, Ismaila AS
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:3105-3118
Published Date: 13 November 2021
Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-Naïve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial
Bjermer L, Boucot IH, Maltais F, Kerwin EM, Naya IP, Tombs L, Jones PW, Compton C, Lipson DA, Vogelmeier CF
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1939-1956
Published Date: 28 June 2021
Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement
Vogelmeier CF, Naya IP, Maltais F, Bjermer L, Kerwin EM, Tombs L, Jones PW, Compton C, Lipson DA, Boucot IH
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:1215-1226
Published Date: 3 May 2021
Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
Kerwin EM, Murray L, Niu X, Dembek C
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2309-2318
Published Date: 29 September 2020
Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow® CS
Stephenson JJ, Dembek C, Caldwell-Tarr A, Conto RM, Paullin M, Kerwin EM
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1713-1727
Published Date: 14 July 2020
An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD
Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2835-2848
Published Date: 6 December 2019
Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD
Crim C, Watkins ML, Bateman ED, Feldman GJ, Schenkenberger I, Kerwin EM, Crawford C, Pudi K, Ho S, Baidoo C, Castro-Santamaria R
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:615-629
Published Date: 8 March 2019
Efficacy of aclidinium/formoterol 400/12 µg, analyzed by airflow obstruction severity, age, sex, and exacerbation history: pooled analysis of ACLIFORM and AUGMENT
D'Urzo AD, Singh D, Donohue JF, Kerwin EM, Ribera A, Molins E, Chuecos F, Jarreta D, Garcia Gil E
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:479-491
Published Date: 26 February 2019
Effect of background long-acting beta2-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
Kerwin EM, Tosiello R, Price B, Sanjar S, Goodin T
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2917-2929
Published Date: 19 September 2018
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
Reisner C, Pearle J, Kerwin EM, St Rose E, Darken P
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1965-1977
Published Date: 19 June 2018
Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD
Kerwin EM, Siler TM, Arora S, Darken P, St Rose E, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1483-1494
Published Date: 8 May 2018
Real-world healthcare utilization in asthma patients using albuterol sulfate inhalation aerosol (ProAir® HFA) with and without integrated dose counters
Kerwin EM, Ferro TJ, Ariely R, Irwin DE, Parikh R
Journal of Asthma and Allergy 2017, 10:171-179
Published Date: 17 May 2017
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study
Kerwin EM, Kalberg CJ, Galkin DV, Zhu C, Church A, Riley JH, Fahy WA
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:745-755
Published Date: 24 February 2017
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data
D’Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D’Andrea P, Hu H, Goyal P, Altman P
International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1599-1612
Published Date: 11 August 2015
Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno C, Knorr B, Shekar T, Banerjee S, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:43-55
Published Date: 3 February 2012
Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials
Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:73-86
Published Date: 3 February 2012
Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD
Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H
International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:57-71
Published Date: 3 February 2012